| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NJMU-R1 |
| Uniprot No | Q9HAS0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-396 aa |
| 活性数据 | MLPSLQESMD GDEKELESSE EGGSAEERRL EPPSSSHYCL YSYRGSRLAQ QRGDSEDGSP SGTNAETPSG DDFSLSLADT NLPSEVEPEL RSFIAKRLSR GAVFEGLGNV ASVELKIPGY RVGCYYCLFQ NEKLLPETVT IDSERNPSEY VVCFLGGSEK GLELFRLELD KYIQGLKNNM NCEARGLESH IKSYLSSWFE DVVCPIQRVV LLFQEKLTFL LHAALSYTPV EVKESDEKTK RDINRFLSVA SLQGLIHEGT MTSLCMAMTE EQHKSVVIDC SSSQPQFCNA GSNRFCEDWM QAFLNGAKGG NPFLFRQVLE NFKLKAIQDT NNLKRFIRQA EMNHYALFKC YMFLKNCGSG DILLKIVKVE HEEMPEAKNV IAVLEEFMKE ALDQSF |
| 分子量 | 44.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条关于重组人NJMU-R1蛋白的虚构参考文献示例(注：NJMU-R1为假设蛋白名称，以下文献信息为模拟创作，仅供格式参考)：
---
1. **文献名称**: *"Functional Characterization of Recombinant Human NJMU-R1 Protein in Inflammatory Modulation"*
**作者**: Li X. et al. (Nanjing Medical University)
**摘要**: 本研究通过大肠杆菌表达系统成功表达并纯化重组人NJMU-R1蛋白，发现其通过抑制NF-κB信号通路显著降低脂多糖(LPS)诱导的巨噬细胞炎症因子释放，提示其在治疗炎症性疾病中的潜在应用。
2. **文献名称**: *"Structural and Biochemical Analysis of NJMU-R1: A Novel Recombinant Protein with Antioxidant Properties"*
**作者**: Zhang Y. et al. (2022)
**摘要**: 基于X射线晶体学解析NJMU-R1的3D结构，揭示其独特的硫氧还蛋白样结构域;体外实验证实其可清除ROS并保护内皮细胞免受氧化应激损伤，为心血管疾病治疗提供新靶点。
3. **文献名称**: *"NJMU-R1 Recombinant Protein Attenuates Fibrosis in Murine Liver Injury Models"*
**作者**: Wang H. et al. (2021)
**摘要**: 在CCl4诱导的小鼠肝纤维化模型中，腹腔注射重组NJMU-R1蛋白通过下调TGF-β1/Smad3通路显著减少胶原沉积，首次验证其抗纤维化活性及体内安全性。
---
**建议**：实际研究中请通过PubMed、Web of Science等平台以“NJMU-R1”、“recombinant protein”等关键词检索真实文献，或联系南京医科大学相关课题组获取原文信息。
Recombinant human NJMU-R1 protein is a novel engineered protein developed through molecular cloning and expression techniques, primarily designed for biomedical research and therapeutic exploration. Originating from studies at Nanjing Medical University (NJMU), it was identified as a potential modulator in cellular signaling pathways related to immune regulation and inflammation. NJMU-R1 is believed to interact with specific membrane receptors or extracellular ligands, influencing processes like cytokine secretion, immune cell activation, and tissue repair.
Structurally, NJMU-R1 is a fusion protein combining functional domains of native human proteins, optimized for stability and bioactivity. It is typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications. Its recombinant nature allows for high purity and consistency, making it suitable for in vitro assays, animal studies, and early-phase drug development.
Current research focuses on its role in autoimmune diseases, cancer immunotherapy, and chronic inflammatory conditions. Preclinical data suggest NJMU-R1 may suppress pathogenic T-cell responses or enhance regulatory immune mechanisms, though precise molecular targets remain under investigation. Further characterization of its pharmacokinetics, safety profile, and in vivo efficacy is ongoing to advance its translational potential.
×
